Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 1617Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 459Carcinoma, Transitional Cell 233Breast Neoplasms 225Kidney Neoplasms 214Neoplasms 190Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 168Ovarian Neoplasms 161Melanoma 161Neoplasm Metastasis 142Lung Neoplasms 127Non-Muscle Invasive Bladder Neoplasms 104Pancreatic Neoplasms 101Stomach Neoplasms 99Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 82Carcinoma, Hepatocellular 76Sarcoma 75Esophageal Neoplasms 71Head and Neck Neoplasms 68Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 45

Interventions

pembrolizumab 1Lutetium-177 1Lutetium 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC) × Genitourinary × 1 year × Clear all
NCT07310355 2025-12-30

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Chengdu StarRay Therapeutics Co., Ltd

Phase 1/2 Not yet recruiting
49 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06241846 2025-08-27

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07104617 2025-08-05

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡